Results 201 to 210 of about 3,152,168 (304)

Primary endpoint acceptance and its association with benefit ratings and market access in German health technology assessments: a retrospective cohort study. [PDF]

Lancet Reg Health Eur
Müller G, Granold M, Busse R, Hahn A.
europepmc   +1 more source

Consensus Formation and Change are Enhanced by Neutrality

Advanced Science, EarlyView.
Neutral agents are shown to enhance both the formation and overturning of consensus in collective decision‐making. A general mathematical model and experiments with locusts and humans reveal that neutrality enables robust consensus via simple interactions and accelerates consensus change by reducing effective population size.
Andrei Sontag, Janina A. Hoffmann, Tim Rogers, Christian A. Yates   +3 more
wiley   +1 more source

A Wearable Brain–Computer Interface for Mitigating Car Sickness via Attention Shifting

Advanced Science, EarlyView.
Car sickness poses a major challenge in vehicular travel, yet effective nonpharmacological solutions are scarce. We developed a wearable, closed‐loop mindfulness BCI that uses real‐time EEG‐based neurofeedback to shift attention away from motion‐induced discomfort. Validated in real‐car experiments involving >100$>100$ susceptible individuals, over 83%
Jiawei Zhu, Xiaoyu Bao, Qiyun Huang, Tao Wang, Li Huang, Haiyun Huang, Junbiao Zhu, Jun Qu, Kendi Li, Di Chen, Ya Jiang, Kailin Xu, Zijian Wang, Wei Wu, Yuanqing Li   +14 more
wiley   +1 more source

Customer Retention in the Philippine Food Sector: Health Measures, Market Access, and Strategic Adaptation After the COVID-19 Pandemic. [PDF]

Foods
Gumasing MJJ.
europepmc   +1 more source

Intelligent Stain‐Free Histology on Structural Colorimetric Nanocavities

Advanced Science, EarlyView.
Chen and Gan et al. introduce a label‐free imaging platform using inexpensive Nanocavity‐on‐Silicon (NOS) slides. These slides transform subtle tissue variations into vivid structural colors, enabling high‐contrast histological imaging under a regular optical microscope. This stain‐free approach reveals morphological details comparable to traditional H&
Qizhe Chen, Yifei Ren, Lijie Hu, Yanyan Li, Wenyue Liang, Jin Wang, Han Gao, Xinhai Wang, Jiajun Li, Qiutao He, Yingfeng Zhu, Haifeng Hu, Qiwen Zhan, Imed Gallouzi, Jasmeen Merzaban, Di Wang, Zunguo Du, Xiaodong Gu, Qiaoqiang Gan   +18 more
wiley   +1 more source

Access in all areas? A round up of developments in market access and health technology assessment: part 7. [PDF]

J Comp Eff Res
Ramagopalan SV, Pannelay AJ.
europepmc   +1 more source

Modulating Integrin and Growth Factor Signaling With Peptides: Strategies to Synergistically Enhance Bone Tissue Regeneration

Advanced Science, EarlyView.
It has been demonstrated that, in the bone extracellular matrix (ECM), integrins and growth factor receptors (GFRs) engage in synergistic signaling to guide bone healing and regeneration. This review provides a comprehensive overview of current strategies using ECM‐derived peptides to recreate the cellular microenvironment and harness synergistic ...
Lluís Oliver‐Cervelló, Elisabetta Ada Cavalcanti‐Adam, Carlos Mas‐Moruno   +2 more
wiley   +1 more source

Future-Proofing European Pharmaceutical Regulatory and Market Access Practices Based on EU Learnings from the COVID-19 Pandemic: Insights from Multi-Stakeholder Interviews. [PDF]

Ther Innov Regul Sci
Claessens Z, Beirne G, Decouttere C, Vandaele N, Barbier L, Huys I.   +5 more
europepmc   +1 more source

Halofuginone is a Molecular Glue Degrader of Integrin β4

Advanced Science, EarlyView.
Integrin β4 overexpression is linked to aggressive tumors and poor prognosis, but targeted therapies are lacking. We identified halofuginone (HF) as a molecular glue degrader that promotes integrin β4 degradation via the CRL4BWDR18 E3 ligase. HF suppresses tumor progression in vitro and in vivo, offering a new strategy for targeting oncogenic ...
Wei Gong, Di Yang, Junrui Tian, Yufei Chai, Tiantian Yu, Qingnan Wu, Yan Wang, Weimin Zhang, Qimin Zhan   +8 more
wiley   +1 more source

Market Access Challenges and Solutions in Cell and Gene Therapy in The Netherlands. [PDF]

J Mark Access Health Policy
Velikanova R, Wolters S, Hofstra HS, Postma MJ, Boersma C.   +4 more
europepmc   +1 more source